



QEEG Clinical Report

BrainLens V0.4

Report Description



Personal & Clinical Data

Name	Mohammadaminhemati	Date of Recording	2025-09-16
Date of Birth - Age	1994-03-23 - 31.6	Gender	Male
Handedness(R/L)	Right	Source of Referral	Kamal Barzegar Ghazi
Initial Diagnosis	Drug Abuse		
Current Medication	-		


Kamal Barzegar Ghazi

Summary Report


EEG Quality




Z-score Information




Compatibility with Depression



Compatibility with Mood Swing




Compatibility with Anxiety




Arousal Level



TMS Responsibility



Cognitive Performance




APF

Posterior APF-EC= 10.50


To investigate QEEG-based predicting medication response, please refer to the Report.

Denoising Information (EC)

Raw EEG



Denoised EEG



Flat Channels



Rejected Channels



Number of Eye and Muscle Elements

Eye 0 Muscle 0

Total Artifact Percentage

0

EEG Quality good

Low Artifact Percentage

0


High Artifact Percentage

0


Total Recording Time Remaining 240.76 sec

Pathological assessment for mood disorders and adult ADHD


Compare to Mood Disorders Database




Compare to Adult ADHD Database




EEG Compatibility with Depression Diagnosis



EEG Compatibility with Anxiety Diagnosis




EEG Compatibility with Mood Swing Diagnosis *



* This index can only be investigated if there are symptoms of mood swings (R/O BMD or R/O mood swings).

Depression and Adult ADHD Diagnosis Probabiliy



Cognitive Functions Aassessment




Arousal Level Detection




Pathological Assessment for Substance Abuse

Relapse Index





Comorbid Symptoms



The **relapse graph** shows the relapse index based on a combination of EEG neuromarkers. If the type of substance your patient uses is included in this chart, you can read its relapse rate. **The condition for using this chart is that the patient consumes each substance specified in the chart.** If your patient does not consume each of the substances specified in the chart, the index shown is not valid.

Substance Abuse Compatibility






The **compatibility graph** shows the compatibility of the patient's EEG neuromarkers and the alternations that the specific substance causes in the EEG. In other words, this chart indicates that your patient has how percentage of validated neuromarkers due to the use of specific substances.

Using this chart, you can figure out how substances have affected EEG and if multiple drugs were used, which one has the most dominant effect. **If your patient does not consume each of the substances specified in the chart, the index shown is not valid.**

Functional Problems Source Detection




Eyes Closed

Freq = 10.5 Hz




*, * NOT Found *, *

Freq = 2 Hz



Brodmann area 46
Inferior Frontal Gyrus
Middle Frontal Gyrus

QEEG based predicting medication response



Explanation

These two tables can be considered the most important finding that can be extracted from QEEG. To prepare this list, the NPCIndex Article Review Team has studied, categorized, and extracted algorithms from many authoritative published articles on predict medication response and Pharmacoe EEG studies. These articles are published between 1970 and 2021. The findings extracted from this set include 85 different factors in the raw band domains, spectrum, power, coherence, and loreta that have not been segregated to avoid complexity, and their results are shown in these diagrams. One can review details in NPCIndex.com .

Medication Recommendation


These two charts, calculate response probability to various medications, according only to QEEG indicators. Blue charts favor drug response and red charts favor drug resistance. The longer the bar, the more evidence there is in the articles. Only drugs listed in the articles are listed. These tables present the indicators reviewed in the QEEG studies and are not a substitute for physician selection.

rTMS Response Prediction


Network Performance

Accuracy: 92.1%
Sensitivity: 89.13%
Specificity: 97.47%


Participants Information




Features Information



Responsibility




Data Distribution




About Predicting rTMS Response

This index was obtained based on machine learning approaches and by examining the QEEG biomarkers of more than 470 cases treated with rTMS. The cases were diagnosed with depression (with and without comorbidity) and all were medication free. By examining more than 40 biomarkers capable of predicting response to rTMS treatment in previous studies and with data analysis, finally 10 biomarkers including bispectral and nonlinear features entered the machine learning process. The final chart can distinguish between RTMS responsive and resistant cases with 92.1% accuracy. This difference rate is much higher than the average response to treatment of 44%, in the selection of patients with clinical criteria, and is an important finding in the direction of personalized treatment for rTMS.

Alpha Asymmetry(AA)




APF(EC)




Frontal APF= 10.50

Posterior APF= 10.50


Absolute Power-Eye Closed (EC)




Relative Power-Eye Closed (EC)




Z Score Summary Information (EC)



E.C.T/B Ratio (Raw- Z Score)



Arousal Level



EEG Spectra

